Skip to Main Content
Contribute Try STAT+ Today

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of pumpkin spice for the occasion. Autumn, after all, is upon us. And so is our ever-growing to-do list. Sound familiar? So, here are some items of interest. Have a great day, everyone …

A World Health Organization-led program to ensure lower-income countries get fair access to Covid-19 vaccines, tests, and treatments aims to secure antiviral drugs for patients with mild symptoms for as little as $10 per course, Reuters reports. A draft document, which outlines the goals of the Access to COVID-19 Tools Accelerator, or ACT-A, until September next year, says that the program wants to deliver about 1 billion Covid-19 tests to lower-income nations, and procure drugs to treat up to 120 million patients globally, out of about 200 million new cases it estimates in the next 12 months. An experimental Merck (MRK) pill is likely to be one of the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment